Differential recognition of "enkephalinase" and angiotensin-converting enzyme by new carboxyalkyl inhibitors

• Published in: Life sciences (1973) Vol. 31; no. 26; p. 2947
• Main Authors: Fournié-Zaluski, M C, Soroca-Lucas, E, Waksman, G, Llorens, C, Schwartz, J C, Roques, B P
• Format: Journal Article
• Language: English
• Published: Netherlands 27.12.1982
• Subjects: Amino Acids - pharmacology; Angiotensin-Converting Enzyme Inhibitors; Animals; Carboxylic Acids - pharmacology; Corpus Striatum - enzymology; Kinetics; Male; Mice; Neprilysin; Protease Inhibitors; Structure-Activity Relationship; Zinc - metabolism
• ISSN: 0024-3205
• DOI: 10.1016/0024-3205(82)90060-1

New carboxylalkyl compounds derived from Phe-Leu and corresponding to the general formula C6H5-CH2-CH(R)CO-L.Leu with R = -COOH, 3, R = -CH2-COOH, 4, R = -NH-CH2-COOH, 5, R = -NH-(CH2)2-COOH, 6, have been found to inhibit the breakdown of the Gly3-Phe4 bond of [3H] Leu-enkephalin or [3H]D.Ala2-Leu-enkephalin resulting from the action of the mouse striatal metallopeptidases: "enkephalinase" or angiotensin-converting enzyme (A.C.E.). The carboxyl coordinating ability of the Zn atom seems to be significantly higher in ACE than in "enkephalinase". Moreover, IC50 values against "enkephalinase" were found in the same range whatever the length of the chain bearing the carboxyl group whereas a well-defined position of this group with respect to the Zn atom is required for strong ACE inhibition. These features suggest a larger degree of freedom of the carboxyalkyl moieties within the active site of "enkephalinase". Therefore the differential recognition of active sites of both peptidases leads to: i) N-(carboxymethyl)-L-Phe-L-Leu, 5, a competitive inhibitor of "enkephalinase" (KI = 0.7 microM) and ACE (KI = 1.2 microM) which could be used as mixed inhibitor for both enzymes; ii) N-[(R,S)-2-carboxy, 3-benzylpropanoyl]-L-Leucine, 3, a full competitive inhibitor of "enkephalinase" (KI = 0.34 microM) which does not interact with ACE (IC50 greater than 10,000 microM). This compound can be considered as the first example of a new series of highly potent and specific "enkephalinase" inhibitors.